IBIO vs SRPT · rev $100.0K vs rev $1.13B
iBio, Inc. Common Stock (IBIO) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
IBIO currently screens at market cap $13.4M. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the IBIO and SRPT stock pages for the full models.
Not investment advice.